Langguth, Berthold http://orcid.org/0000-0002-7066-510X
de Ridder, Dirk
Schlee, Winfried
Kleinjung, Tobias
Funding for this research was provided by:
Universität Regensburg
Article History
Received: 28 December 2023
Accepted: 26 February 2024
First Online: 26 March 2024
Declarations
:
: B. Langguth received honoraria for consultancy and speakers’ fees from ANM, AstraZeneca, Autifony Therapeutics, Decibel Therapeutics, Desyncra, Gerson Lehmanns Group, Lundbeck, Merz, MagVenture, Medical Tribune, Neurolite, Neuromod, Novartis, Pfizer, Rovi, Schwabe, Sea Pharma, Servier, Sonova and Sound Therapeutics; research funding from the Tinnitus Research Initiative, Bayhost, the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the American Tinnitus Association, AstraZeneca, cerbomed, Neuromod and the European Union; funding for equipment from MagVenture and Deymed Diagnostic; and travel and accommodation payments from Eli Lilly, Lundbeck, Servier, and Pfizer. He owns shares of Sea Pharma. D. De Ridder received honoraria for consultancy and speakers’ fees from Abbott laboratories and research funding from ATA and TRI. W. Schlee received honoraria for consultancy and speakers’ fess from Schwabe, Pohl-Boskamp, and Pansatori. He received funding from the EU, the Bavarian Research Foundation, the German Research Foundation, Innosuisse, and the Rainwater Charitable Foundation. He is stakeholder of the Lenox uG and the HealthStudyClub GmbH, which aim to translate scientific knowledge into digital health applications. T. Kleinjung received honoraria for consultancy and speaker’s fees form Sonova and Schwabe and travel and accommodation payments from Cochlear. His research was funded from the Tinnitus Research Initiative, the Swiss National Science Foundation, the European Union, the Zurich Hearing Foundation and Cochlear.